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Abstract 
Background and objectives: Ketamine and propofol are the general anesthetics that also have 
antimicrobial and microbial growth-promoting effects, respectively. Although these agents 
are frequently applied together during clinical use, there is no data about their total effect 
on microbial growth when combined. In this study, we investigated some organisms’ growth 
in a ketamine and propofol mixture.
Method: We used standard strains including Escherichia coli, Staphylococcus aureus, 
Pseudomonas aeruginosa, and Candida albicans in this study. Time-growth analysis was 
performed to assess microbial growth rates in 1% propofol. Antimicrobial activity of ketamine, 
alone and in propofol was studied with microdilution method.
Results: In propofol, studied strains grew from 103-104 cfu/mL to ≥105 cfu/mL concentrations 
within 8-16 hours depending on the type of organism. Minimal inhibitory concentration (MIC) 
and minimal bactericidal concentration (MBC) (for candida, minimal fungicidal concentration) 
of ketamine were determined as follows (MIC, MBC): E.coli 312.5, 312.5 μg/mL; S.aureus 
19.5, 156 μg/mL; P.aeruginosa 312.5, 625 μg/mL; and C.albicans 156, 156 μg/ml. In 
ketamine+propofol mixture, ketamine exhibited antimicrobial activity to E.coli, P.aeruginosa 
and C.albicans as MBCs at 1250, 625 and 625 μg/mL, respectively. Growth of S. aureus was 
not inhibited in this mixture (ketamine concentration=1250 μg/mL).
Conclusion: Ketamine has sustained its antimicrobial activity in a dose-dependent manner 
against some organisms in propofol, which is a strong microbial growth-promoting solution. 
Combined use of ketamine and propofol in routine clinical application may reduce the risk of 
infection caused by accidental contamination. However, one must keep in mind that ketamine 
cannot reduce all pathogenic threats in propofol mixture. 
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Propofol is a widely used sedative-hypnotic drug that 
is administered in the induction and maintenance of 
anesthesia. Propofol is considered as a good microbial 
growth-promoting agent due to its rich nutritional content, 
like soybean oil, glycerol, and egg lecithin.1,2 Accordingly, 
severe infections have been reported in patients following 
the use of contaminated propofol.3,4
Ketamine is a general anesthetic that has an 
antagonist effect on the n-methyl d-aspartate receptors. 
It is characterized by rapid onset of actions, including 
analgesia, anesthesia, elevated blood pressure, and 
dilatation in lower airways. Considering its favorable 
effects on the cardiovascular and pulmonary system, 
ketamine may be particularly valuable for induction 
of anesthesia in a hypovolemic patient.5,6 Additionally, 
some studies have documented ketamine’s antimicrobial 
activity.7,8
Combination of ketamine and propofol (ketofol) is shown 
to be pharmaceutically compatible when applied in the 
same syringe. Several studies have reported that ketofol 
has positive regulatory activity on the hemodynamic 
parameters in human volunteers.9-11 Regarding the high 
microbial growth-promoting effect of propofol and 
antimicrobial activity of ketamine, investigation of the 
total effect of their combination on the growth of some 
bacteria and yeast was thought to be valuable. Therefore, 
we conducted an in vitro study to determine the effect 
of ketofol mixture on some clinically important organisms 
that were the significant pathogens of hospital-acquired 
infections in the world. 
Materials and methods
Drugs and microorganisms
We used ketamine (Ketalar® 50mg/ml Pfizer), and1% propofol 
(Propofol® %1 Fresenius) in this study. Drug mixtures were 
prepared in aseptic conditions. 
In this study, we used the following standard strains: 
Escherichia coli (ATCC 25922) (RSHM/Turkey), Staphylococcus 
aureus (ATCC 29213) (Oxoid/UK), Pseudomonas aeruginosa 
(ATCC 27853) (Oxoid/UK) and Candida albicans (ATCC 
14053) (Oxoid/UK). 
Microbial-growth-promoting activity of propofol
We studied growth rates of the tested microorganisms 
in time-growth analyses. Briefly, we selected bacterial 
and fungal colonies grown on nutrient agar plates and 
suspended in sterile 0.9% physiologic saline at McFarland 
0.5 density. These suspensions were re-suspended in 
propofol to adjust final concentration of organisms 
to 1-2x104 bacteria per mL, and 4-5x103 yeast per mL. 
We incubated these suspensions at 35oC for 24 hours. In 
2-hour periods, subcultures to nutrient agar mediums 
were performed between 0 and 24 hours. We read the 
number of colony-forming units (cfu/mL) grown on the 
plates visually by single investigator.
Antimicrobial activity of ketamine
We investigated the impact of ketamine, alone and in 
propofol mixture, on microbial growth rates of each 
organism with microdilution method according to published 
standards for antimicrobial susceptibility tests by Clinical 
and Laboratory Standards Institute (CLSI),12,13 and previously 
published study by Gocmen et al.7 We accepted the ketamine 
concentration that was associated with 100% inhibition of 
yeast growth as MIC value for C. albicans.
Antimicrobial activity of ketamine  
in standard tests
Briefly, we serially diluted ketamine in 100 μL cation 
adjusted Mueller Hinton Broth (Himedia/India) (for 
bacterial strains), and in MOPS (Applichem GmbH/
Germany)-buffered RPMI 1640 (Sigma/Germany) liquid 
medium (for candida) in sterile plysteren 96-well plates. 
Then, we prepared bacterial and fungal suspensions in 
sterile 0.9% physiologic saline at McFarland 0.5 density. We 
re-suspended these suspensions in their standard broths. 
A 100 μL volume of inoculums was distributed into each 
well. Final ketamine concentrations ranged from 1250 to 
1.22 μg•mL–1 in the wells with 2.5-5x104 cfu•mL–1 inoculums 
of bacteria, or 1-5x103 cfu•mL–1 inoculums of candida. After 
24-h incubation at 35oC, we determined minimal inhibitory 
concentrations (MIC) by visual reading. For candida strain, 
100% inhibition was accepted as the MIC value regarding 
the drug-free inoculums control. We determined minimal 
bactericidal concentrations (for candida, minimal fungicidal 
concentration) (MBC) by performing subcultures from the 
wells showing inhibition of visible bacterial of fungal growth 
to appropriate nutrient agar mediums. We accepted the 
drug concentration in the well that had 99.9% inhibition of 
the tested strain as the MBC. We prepared control cultures 
for microorganisms, broth, and drug solution.
Antimicrobial activity of ketamine in propofol
We serially diluted ketamine in propofol solution in 
sterile plysteren 96-well plates. The bacterial and fungal 
suspensions prepared in sterile 0.9 % physiologic saline at 
McFarland 0.5 density were re-suspended in propofol, and 
distributed into each well as equal aliquots. Final ketamine 
concentrations ranged from 1250 to 1.22 μg/mL in the wells 
with 2.5-5x104 cfu•mL–1 inoculums of bacteria, or 1-5x103 
cfu•mL–1 inoculums of candida. After 24-h incubation at 
35oC, we determined MBCs by performing subcultures from 
the wells onto the appropriate agar mediums as described 
above. We performed control cultures for microorganisms, 
propofol and drug solution.
Results
Microbial growth in propofol 1%
Fig. 1 shows growth rates of the tested strains in propofol 
1% suspension. At the first two hours of the incubation, we 
detected no significant growth for E. coli, P. aeruginosa, 
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and S. aureus regarding time zero. But, the concentration of 
C. albicans doubled (from 5x103 cfu•mL–1 to 1x104 cfu•mL–1) 
within the same interval. E. coli and P. aeruginosa reached 
≥ 1x105 cfu•mL–1 concentration at 10th and 8th hours of 
incubation, C. albicans at 14th hours, and S. aureus at 16th 
hours.
Antimicrobial activity of ketamine in standard 
tests, and in propofol mixture
Ketamine showed an in vitro antimicrobial effect against 
all tested strains in standard antimicrobial susceptibility 
tests. We determined the lowest ketamine MIC for S. aureus 
as19.5 μg•mL–1; and measured the highest MIC for E. coli 
and P. aeruginosa as 312.5 μg•mL–1. Regarding the MBCs 
of ketamine, we detected the lowest value for S. aureus 
and C. albicansas 156 μg•mL–1, and determined the highest 
value for P. aeruginosa as 625 μg•mL–1.
In propofol mixture, ketamine MBCs for P. aeruginosa and 
C. albicanswere measured as 625 μg•mL–1, and for E. coli 
1,250 μg•mL–1. We could not determine MBC of S. aurues 
(MBC > 1,250 μg•mL–1), as no inhibition occurred.
Table 1 shows the measured MIC and MBC values of 
ketamine for each organism.
Discussion
In this study, we determined that propofol was a strong 
microbial growth promoting solution not only for bacteria 
but also for funghi. Considering the organisms’ types, gram 
negatives, P. aeruginosa and E. coli, showed the fastest 
growth index, reaching 1x105 cfu•mL–1 concentration within 
8 and 10 hours, respectively, while C. albicans reached this 
concentration at the 14th hour. However, S. aureus had 
relatively the slowest growth rate among all tested strains 
(Fig. 1). 
Ketamine is a drug that is primarily used for the 
induction and maintenance of general anesthesia. It is a 
core medicine which is categorized in the World Health 
Organization’s “Essential Drug List”.14 Ketamine has a 
wide range of effects on humans, including analgesia, 
anesthesia, hallucinations, elevated blood pressure, and 
bronchodilation. In 2008, Gocmen et al.7 published an in vitro 
study reporting that ketamine had antimicrobial activity 
against some streptococci, staphylococci, E. coli, and P. 
aeruginosa between 500-2,000 μg•mL–1 concentrations. As 
for the fact that anesthetic blood level of ketamine was 
about 2 μg•mL–1, they state that this antibacterial activity 
cannot be seen in humans during anesthesia. 
Table 1 Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values of ketamine alone and 
in propofol mixture for the studied organisms.
Organisms Ketamine Ketamine + Propofol
 MICs (μg•mL–1) MBCs (μg•mL–1) MBCs (μg•mL–1)
E. coli 312.5 312.5 1,250
S. aureus 19.5 156 > 1,250
P. aeruginosa 312.5 625 625
C. albicans 156 156 625a
a Minimal fungicidal concentration.
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Figure 1 Growth rates of the organisms in 1% propofol solution in 2-h periods.
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We observed that ketamine had a potential antibacterial 
and antifungal activity on the tested strains. Regarding the 
organisms’ types, we found P. aeruginosa and E. coli to be 
more resistant, and S. aureus were the most susceptible 
to ketamine. We detected that S. aureus had 5 logs lower 
MIC and 2 logs lower MBC values than the gram negatives. 
On the other hand, MIC and MBC values of ketamine for C. 
albicans were equal in this experiment. 
In this study, we investigated the antimicrobial activity 
of ketamine in propofol mixture. This mixture has been 
used successfully in different clinical situations including 
monitored care anesthesia, electroconvulsive therapy, 
procedural sedation, and analgesia in emergency 
patients.9-11,15 In the ketofol mixture, we detected that 
ketamine sustained its antibacterial and antifungal activities 
at higher MBCs. In our study, we could not measure MICs of 
ketamine in propofol, due to fact that turbid solution was 
formed in the microplates following the propofol inclusion, 
which did not allow for clear visual evaluation. Therefore, 
we detected only MBCs of ketamine in the ketofol mixture. 
Regarding the tested strains, we observed twofold increase 
in the MBC values of ketofol mixture for E. coli and 
C. albicans. However, a certain MBC of ketofol was not 
determined for S. aureus, due to fact that its value was 
over the test’s detection limit. Interestingly, MBC of this 
mixture did not change in comparison to ketamine alone, 
and remained stable for P. aeruginosa at 625 μg•mL–1. 
Infection is a considerable concern during the clinical 
use of propofol. Particularly because of its lipid base, 
propofol provides a preferable media for many classes 
of microorganisms. Therefore, nosocomial postoperative 
infections which impose heavy burden of morbidity and 
mortality and have serious economic consequences can 
develop due to the contamination of propofol.16 Mueller et 
al.4 reported an outbreak of sepsis caused by gram negative 
organisms including Klebsiella pneumoniae and Serratia 
marcescens in 7 patients, due to contaminated propofol 
use in minor surgical procedures. Similarly, Henry et al.17 
reported postoperative bacteremia and wound infections 
caused S. marcescens, following the propofol use in Canada. 
Additionally, Bennett et al.18 reported propofol-related 
infections including bloodstream infections, surgical site 
infection, and acute febrile episodes in 62 cases, after 
surgical procedures in seven US hospitals. They identified 
S. aureus, C. albicans and gram-negative bacteria such 
as morexella, enterobacter and serratia species to be 
responsible for these infections. In all these studies, 
the authors emphasized that extrinsic contamination of 
propofol, as a result of the lapses in aseptic preparation, 
handling and storage of this drug, caused these life-
threatening infections. 
Center of Disease Control and Prevention suggested safe 
medication practices, including avoiding the use of syringes 
on multiple patients as well as avoiding single-use medication 
vials for multiple patients, and strictly adhering to aseptic 
techniques and infection control practices during propofol 
application.19 Additionally, in order to reduce the incidence 
of propofol-related postoperative infection, antimicrobial 
preservative-containing (i.e., EDTA- or Na-metabisulphide-
containing) emulsions have been manufactured according 
to discussion with the Food and Drug Administration Agency 
(FDA). Such formulations are used in the United States 
today; nevertheless, preservative-free propofol solutions 
are still being marketed in Europe and in other areas of 
the world. Jansson et al.16 reported that the incidence of 
propofol-related infection reduced from 39 to 9 infections 
per year in the U.S., after onset of EDTA-containing 
propofol use in 1996. However, as the infection problem 
with propofol continued despite of preservative inclusion, 
they have underlined that addition of EDTA is only an 
additional safety precaution. Hence, the practitioner must 
regard to good aseptic practice in any occasion during 
propofol medication. In this study, we tested preservative-
free emulsion of propofol, which was also used in our 
hospital. Though antimicrobial-added propofol is also being 
marketed in our country, preservative-free forms are widely 
preferred possibly due to economic concerns.
Propofol and ketamine are unlicensedly mixed as 1:1 
volumes before clinical application, achieving 5 mg•mL–1 
ketamine in this mixture. Since Gocmen et al.7 reported that 
blood levels of ketamine were too low to not to show any 
antimicrobial effect in the body, we investigated whether 
it could prevent the microbial growth in propofol. In this 
study, we observed that MBCs of ketamine in ketofol mixture 
were between 625 and 1,250 μg•mL–1 (> 1,250 μg•mL–1 for 
S. aureus). Therefore, we thought that ketamine might 
be useful to reduce growth of some bacterial and fungal 
pathogens in propofol before application. 
In this study, we found that particularly gram-negative 
bacteria rapidly grew in propofol solution. These results 
are interestingly parallel with the data that is previously 
reported from the outbreak studies.3,4,17,18 We thought that 
this selective promotion of propofol for the gram-negatives 
might explain why such bacteria would be the leading 
pathogens of the nosocomial outbreaks related to propofol 
use.
In this study, we showed that inclusion of ketamine 
into propofol might reduce bacterial and fungal growth in 
this solution and, consequently, provide a safe anesthetic 
medication for surgical approaches. However, ketamine’s 
activity may vary according to type of organism. Therefore, 
regardless of this safeguard, we underlined that strict 
hygienic measurements must be taken in any occasion of 
propofol use, according to the recommendations of the 
authorities.
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